Endo International plc - Ordinary Shares (ENDP) Company Bio
Endo International plc focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The company was founded in 1920 and is based in Dublin, Ireland.
ENDP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Endo International plc. To summarize, we found that Endo International plc ranked in the 22th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Endo International plc, consider:
Its compound free cash flow growth rate, as measured over the past 5.69 years, is -0.04% -- higher than only 19.42% of stocks in our DCF forecasting set.
13% of the company's capital comes from equity, which is greater than merely 3.87% of stocks in our cash flow based forecasting set.
As a business, Endo International plc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ENDP, try ABT, CPIX, DHR, EHC, and RHE.
DUBLIN, Aug. 21, 2020 /PRNewswire/ -- Endo International plc (the "Company") (NASDAQ: ENDP) announced today the expiration and final tender results of the previously announced cash tender offer (the "Offer") by its wholly owned subsidiary Endo Finance LLC ("Endo Finance") for any and all…
Los Angeles, CA - (NewMediaWire) - August 12, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Endo International plc (“Endo” or “the Company”) (NASDAQ: ENDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 8, 2017 and June 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before August 18, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Endo securities between August 8, 2017, and June 10, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/endp. This clas
Endo International plc (ENDP) Q2 2020 Earnings Conference Call August 06, 2020 7:00 AM ET Company Participants Laure Park – Senior Vice President of Investor Relations and Corporate Affairs Blaise Coleman – President and Chief Executive Officer Mark Bradley – Executive Vice President and Chief Financial Officer Patrick Barry –...
The U.S. Department of Justice is demanding OxyContin maker Purdue Pharma pay as much as $18.1B in penalties as part of its bankruptcy reorganization plan, WSJ reports.On the civil side, the DOJ is seeking $2.8B - which could be tripled under the law - for tax dollars spent battling the...